Diphenylpyraline Hydrochloride
FDA-approved product (capsule, extended release, oral), marketed as Hispril.
- Registered studies
- 0
- Lab records
- 1
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Aminoalkyl ethers
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Diphenylpyraline Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis10.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
- M. tuberculosis: measured active in 0 of 1 lab record
Show the 1 laboratory record, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Diphenylpyraline Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Abiraterone AcetateExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more62.1% AI-predicted activityagainst MRSA22 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.0% AI-predicted activityagainst MRSA50+ registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more62.0% AI-predicted activityagainst MRSA50+ registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection61.9% AI-predicted activityagainst MRSA50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis61.6% AI-predicted activityagainst MRSA43 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.6% AI-predicted activityagainst MRSA50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more61.5% AI-predicted activityagainst MRSA50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease61.5% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.